Effect of clofibrate in jaundiced full-term infants: A randomized clinical trial

Archives of Iranian Medicine

Volumn 10, Issue 3, 2007, Pages 349-353

  Zahedpasha, Yadollah ^a,c   Ahmadpour Kacho, Mousa ^a   Hajiahmadi, Mahmood ^a   Naderi, Salma ^b  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Amirkola Children's Hospital Babol   (Iran)

Author keywords

Bilirubin; Clofibrate; Jaundice; Neonate

Indexed keywords

BILIRUBIN; CLOFIBRATE; PLACEBO; WATER;

ABSENCE OF SIDE EFFECTS; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HIGH RISK INFANT; HUMAN; LENGTH OF STAY; MALE; NEWBORN; NEWBORN JAUNDICE; OUTCOME ASSESSMENT; PHOTOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTILIPEMIC AGENTS; BILIRUBIN; CLOFIBRATE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFANT, NEWBORN; JAUNDICE, NEONATAL; LENGTH OF STAY; MALE; PHOTOTHERAPY; TREATMENT OUTCOME;

EID: 34547403742     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Janjindamai W, Tansantiwong T. Accuracy of transcutaneous bilirubinometer estimates using Bilicheck in Thai neonates. J Med Assco Thai. 2005; 88: 187-190.
2. Huang MJ, Kua KE, Teng KS, Weng HW, Huang CS. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res. 2004; 56: 677-678.
3. Sanpavat S, Nuchprayoon I. Noninvasive transcutaneous bilirubin as a screening test to identify the need for serum bilirubin assessment. J Med Assoc Thai. 2004; 87: 1193-1198.
4. Agrawal R, Aggarwal R, Deorari AK, Paul VK. Jaundice in the newborn. Indian J Pediatr. 2001; 68: 977-980.
5. Dennery PA. Pharmacological interventions for the treatment of neonatal jaundice. Semin Neonatal. 2002; 7: 111-119.
6. Rubaltelli FF. Current drug treatment options in neonatal hyperbilirubinemia and the prevention of kernicterus. Drugs. 1998; 56: 23-30.
7. Hansen TW. Therapeutic approaches to neonatal jaundice: an international survey. Clin Pediatr (Phila). 1996; 35: 309-316.
8. Jain R, Tiwari M, Chandra R, Prakash GU. The use of riboflavin and metalloporphyrins in cytochrome P-450 content in Wistar rats. Artif Cells Blood Substit Immobil Biotechnol. 2005; 33: 271-278.
9. Weisz B, Belson A, Milbauer B, Reif S. Complications of exchange transfusion in term and preterm newborns. Harefuah. 1996; 130: 170-173; 223.
10. Brun S, Carmona MC, Mampel T, Vinas 0, Giralt M, Iglesias R, et al. Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth. Diabetes. 1999; 48: 1217-1222.
11. Bourget P, Broise I, Quinquis-Desmaris V, Gabilan JC. Pharmacokinetics of clofibrate in jaundiced newborn infants at term. Arch Pediatr. 1995; 2: 722-728.
12. Kutz K, Kandler H, Gugler R, Fevery J. Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert,s syndrome. Clin Sci (Lond). 1984; 66: 389-397.
13. Lindenbaum A, Hernandorena X, Vial M, Benattar C, Janaud JC, Dehan M, et al. Clofibrate for the treatment of hyperbilirubinemia in neonates born at term: a double blind controlled study. Arch Fr Pediatr. 1981; 38 (suppi 1): 867-873.
14. Bucheli Jiménez ER, Quiróz Maldonado M, Flores Colín I. Chlorifibrate effect associated with phototherapy on bilirubin concentration in newly-born babies. Rev Mex Pediatr. 2001; 68: 176-180.
15. Lindenbaum A, Delaporte B, Benattar C, Dehan M, Magny JF, Gerbet D, et al. Preventive treatment of jaundice in premature newborn infants with clofibrate. Double-blind controlled therapeutic trial. Arch Fr Pediatr. 1995; 42: 759-763.
16. Mohammadzadeh A, Farhat AS, Iranpour R. Effect of clofibrate in jaundiced term newborns. Indian J Pediatr. 2005; 72: 123-126.
17. Steiner A, Weisser B, Vetter W. A comparative review of the adverse effects of treatments for hyperlipidaemia. Drug Saf. 1991; 6: 119-130.
18. Gabilan JC. Pharmacologic treatment of neonatal jaundice. A new approach. Arch Pediatr. 1998; 5: 1274-1278.
19. Whitelaw A. Postnatal phenobarbital for the prevention of intraventricular hemorrhage in preterm infants. Cochrane Database Syst Rev. 2000; (2): CD001691.
20. Hansen TW, Tommarello S. Effect of phenobarbital on bilirubin metabolism in rat brain. Biol Neonate. 1998; 73: 106-111.
21. Kappas A, Drummond GS, Valaes T. A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns. Pediatrics. 2001; 108: 25-30.
22. Valaes T, Drummond GS, Kappas A. Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns using an inhibitor of bilirubin production, Sn-mesoporphyrin. Pediatrics. 1999; 103: 536-537.